Boston court rules in favor of AstraZeneca's 'pay-for-delay' deal involving Nexium
A federal jury in Massachusetts has ruled in favor of AstraZeneca Plc and Ranbaxy Laboratories following accusations that the companies delayed the launch of a generic version of the heartburn drug Nexium, sparing the companies potentially billions in damages.
The verdict was handed down Friday in federal court in Boston.
The lawsuit began in 2012 and was filed by plaintiffs including drug wholesalers, retailers and insurance companies. The plaintiffs claimed that the two companies agreed to a… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 6, 2014 Category: Pharmaceuticals Authors: Mary Moore Source Type: news
AstraZeneca, Ranbaxy prevail in Nexium antitrust trial
The US Federal Trade Commission estimates that pay-for-delay deals, in which a branded drugmaker pays a generic rival to stay off the market, cost consumers $3.5 billion each year. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 5, 2014 Category: Pharmaceuticals Source Type: news
US court refuses Ranbaxy appeal to block ANDA nod for 2 drugs
Ranbaxy Laboratories had sued USFDA over revoking an approval to sell generic versions of Nexium and Valcyte in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 26, 2014 Category: Pharmaceuticals Source Type: news
U.S. Court Overturns Ranbaxy's Bid to Block Rival Generics
A U.S. court has denied a request by India's Ranbaxy Laboratories to stop competitors from launching generic copies of AstraZeneca's heartburn pill Nexium and Roche's antiviral, Valcyte. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 20, 2014 Category: Pharmaceuticals Source Type: news
Ranbaxy Sues FDA Over Revoked Generic Approvals
Ranbaxy Laboratories has sued the U.S. FDA for revoking approvals granted to launch generic copies of AstraZeneca's Nexium and Roche's Valcyte. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 18, 2014 Category: Pharmaceuticals Source Type: news
Ranbaxy sues FDA over revoking approvals for Nexium, Valcyte copies
"FDA has no power to correct an alleged mistake it made six years ago," Ranbaxy said in the court filing dated Nov. 14 and seen by Reuters on Tuesday. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 18, 2014 Category: Pharmaceuticals Source Type: news
U.S. Pulls Approval for Copies of AstraZeneca, Roche DrugsU.S. Pulls Approval for Copies of AstraZeneca, Roche Drugs
The U.S. Food and Drug Administration has revoked a tentative approval for India's Ranbaxy Laboratories to make a cheap copy of AstraZeneca's heartburn drug Nexium, after its Indian plants were banned over quality control issues. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 7, 2014 Category: Consumer Health News Tags: Pharmacist News Source Type: news
FDA Revokes Ranbaxy's Approval to Make AstraZeneca and Roche Generics
The U.S. FDA has revoked a tentative approval for India's Ranbaxy Laboratories to make inexpensive copies of AstraZeneca's heartburn drug Nexium, as well as Roche Holding's antiviral Valcyte. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 6, 2014 Category: Pharmaceuticals Source Type: news
U.S. pulls approval for Ranbaxy copies of AstraZeneca and Roche drugs
MUMBAI (Reuters) - The U.S. Food and Drug Administration (FDA) has revoked a tentative approval for India's Ranbaxy Laboratories Ltd to make a cheap copy of AstraZeneca Plc's heartburn drug Nexium, after its Indian plants were banned over quality control issues. (Source: Reuters: Health)
Source: Reuters: Health - November 6, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
Ranbaxy Laboratories still has exclusive rights for Nexium generic: CEO Arun Sawhney
Ranbaxy was first to seek approval from US FDA to sell a cheaper copy of Nexium, gaining exclusive rights to sell it for 6 months after patent expiry. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 28, 2014 Category: Pharmaceuticals Source Type: news
Indian drugmaker Ranbaxy still has exclusive rights for Nexium generic: CEO
MUMBAI (Reuters) - Indian drugmaker Ranbaxy Laboratories still has exclusive rights to the launch of AstraZeneca's heartburn drug Nexium in the United States, it said on Tuesday, despite regulatory concern over the manufacturing process. (Source: Reuters: Health)
Source: Reuters: Health - October 28, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
Connecticut AG George Jepsen to USFDA: Pull up Ranbaxy for failing to launch drug Nexium
Ranbaxy was scheduled to launch the generic version of drug Nexium in US under a 6-month exclusive marketing opportunity, but it failed to do. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 12, 2014 Category: Pharmaceuticals Source Type: news
Longterm Use of Heartburn Medication May Lead To Bone Loss
BOSTON (CBS) – Grace Tejchman has been taking heartburn medications for nine years now. She says she needs the relief from some difficult symptoms.
“If I don’t take it, the acid backs up and I have severe heartburn and a ball in my throat,” she said.
The relief comes from a group of drugs known as Proton Pump Inhibitors. They’re excellent at controlling heartburn by reducing the amount of acid produced in the stomach. These drugs are sold as Prevacid, Nexium, and Prilosec.
Many of these medications started as prescriptions in the late 1980s, but are currently available over the counter. Now that they have bee...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 17, 2014 Category: Consumer Health News Authors: miketoole Tags: Health Local News Seen On WBZ-TV Syndicated Local Watch Listen Bone Loss CBS Boston Dr. Blair Jobe Dr. Mallika Marshall Heartburn Medication Proton Pump Inhibitors WBZ TV Source Type: news
06.03.14 -- Pfizer Launches OTC Nexium For Heartburn; AstraZeneca's Focus On Supply Chain
06/03/14Pharmaceutical Online Newsletter (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - June 2, 2014 Category: Pharmaceuticals Source Type: news
Using Acid Reflux Medications Wisely
If you decide to take medication for any medical condition, you should know how to take that medication wisely. Up to half of all those who take medications do not take them as directed. This could be the result of not reading the labels on the prescriptions bottles or on the bottles of the over the counter meds, missing doses, using medication after it's expiration date, etc.
In order to make sure you lower your risk of having problems with the medications you take, you can follow the tips in this article on using medications wisely.
Related Resources:
Antacids
Maalox
Mylanta
Tums
Gaviscon
Chooz
...
Source: About Heartburn / Acid Reflux - May 9, 2014 Category: Consumer Health News Source Type: news
